Reference : Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarb...
Scientific journals : Article
Human health sciences : Neurology
Systems Biomedicine
http://hdl.handle.net/10993/50343
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
English
Krüger, Rejko mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Translational Neuroscience >]
Pavelka, Lukas mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Translational Neuroscience >]
Mollenhauer, Brit [Paracelsus-Elena-Klinik > Center of Parkinsonism and Movement Disorders]
Bloem, Bas [Radboud University Medical Center > Department of Laboratory Medicine]
van Rumund, Anouke [Radboud University Medical Center > Department of Neurology]
Esselink, Rianne A. J. [Radboud University Medical Center > Department of Neurology]
Geurtz, Ben P M [Radboud University Medical Center > Department of Laboratory Medicine]
Wevers, Ron A. [Radboud Universiteit Nijmegen > Department of Laboratory Medicine]
Verbeek, Marcel M. [Radboud Universiteit Nijmegen > Department of Laboratory Medicine]
19-Mar-2021
NPJ Parkinson's Disease
Nature Publishing Group
Yes (verified by ORBilu)
International
2373-8057
New-York
NY
[en] Parkinson's disease ; Peripheral decarboxylase inhibitors (PDIs) ; levodopa
[en] Peripheral decarboxylase inhibitors (PDIs) prevent the conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed in many patients with Parkinson’s disease. We evaluated the effect of levodopa/PDI use on serum AADC enzyme activity. Serum AADC enzyme activity was evaluated in three independent cohorts of patients with Parkinson’s disease or parkinsonism (n = 301) and compared between patients on levodopa/PDI vs. patients not on this medication. AADC enzyme activity was elevated in 62% of patients on levodopa/PDI treatment, compared to 19% of patients not on levodopa/PDI (median 90 mU/L vs. 50 mU/L, p < 0.001). Patients with elevated AADC activity had longer disease duration and higher doses of levodopa/PDI. These findings may implicate that peripheral AADC induction could underlie a waning effect of levodopa, necessitating dose increases to maintain a sustained therapeutic effect.
Researchers ; Professionals ; Students
http://hdl.handle.net/10993/50343
10.1038/s41531-021-00172-z
https://www.nature.com/articles/s41531-021-00172-z
Open Access
FnR ; FNR11264123 > Rejko Krüger > NCER-PD > Ncer-pd > 01/01/2015 > 30/11/2020 > 2015

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
41531_2021_Article_172_Peripheral.pdfArticlePublisher postprint654.22 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.